Zimmer Biomet Holdings, Inc. $ZBH Shares Bought by Swiss National Bank

Swiss National Bank raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 581,700 shares of the medical equipment provider’s stock after buying an additional 38,800 shares during the quarter. Swiss National Bank’s holdings in Zimmer Biomet were worth $52,597,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. DV Equities LLC purchased a new position in shares of Zimmer Biomet during the fourth quarter worth approximately $25,000. Monetary Solutions Ltd acquired a new stake in Zimmer Biomet during the 4th quarter worth $30,000. Gen Wealth Partners Inc acquired a new stake in Zimmer Biomet during the 4th quarter worth $31,000. Flagship Harbor Advisors LLC purchased a new position in Zimmer Biomet during the 4th quarter worth $32,000. Finally, Cornerstone Financial Management LLC acquired a new position in Zimmer Biomet in the fourth quarter valued at $37,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ZBH shares. Wall Street Zen cut shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. BMO Capital Markets started coverage on Zimmer Biomet in a report on Wednesday, July 8th. They set a “market perform” rating and a $95.00 price target on the stock. Barclays reduced their price objective on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research note on Wednesday, April 29th. Weiss Ratings cut Zimmer Biomet from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday. Finally, JPMorgan Chase & Co. lowered their target price on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and an average price target of $100.70.

Zimmer Biomet Stock Down 0.1%

ZBH stock opened at $88.79 on Thursday. The stock has a market capitalization of $17.18 billion, a PE ratio of 23.06, a price-to-earnings-growth ratio of 2.62 and a beta of 0.46. The company has a fifty day moving average of $87.61 and a 200-day moving average of $89.80. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $108.29.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. The business had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business’s revenue was up 9.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be given a dividend of $0.24 per share. The ex-dividend date is Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s payout ratio is presently 24.94%.

Insider Activity

In other news, insider Sang Yi sold 5,000 shares of the stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.28% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.